(+/-)-2-hydroxy-2-(thienyl)-4-pentenoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: (+/-)-2-hydroxy-2-(thienyl)-4-pentenoic acid
• 英文别名: 2-Hydroxy-2-thiophen-2-ylpent-4-enoic acid
• 化学式: C₉H₁₀O₃S
• 分子量: 198.243
• InChiKey: LHQBTFFNZZYCJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-噻吩乙醛酸 、 丙烯基三氯硅烷 在 六甲基磷酰三胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以96%的产率得到(+/-)-2-hydroxy-2-(thienyl)-4-pentenoic acid
  参考文献：
  名称：

  Chemoselective allylic addition of allyltrichlorosilane to α-oxocarboxylic acids: synthesis of tertiary α-hydroxy carboxylic acids

  摘要：

  Allyltrichlorosilane can add to alpha-oxocarboxylic acids in the presence of DMF and HMPA. The alpha-carboxylic substituent exerts a remarkable neighboring group effect on the reaction, The reaction presumably proceeds in an intramolecular fashion through a 'rigid' bicyclic transition state assembly involving a hypervalent silicate species, which produces the chemoselectivity approaching 100%. (C) 2000 Dupont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00692-4

文献信息

• Novel quinuclidine derivatives and medicinal compositions containing the same
  申请人：——

  公开号：US20040072863A1

  公开（公告）日：2004-04-15

  A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group, —OR 7 , —SR 7 , —NR 7 R 8 , —NHCOR 7 , —CONR 7 R 8 , —CN, —NO 2 , —COOR 7 or CF 3 group, or a strait or branched, substituted or unsubstituted lower alkyl group, wherein R 7 and R 8 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic or alicyclic ring or a heterocyclic group. n is an integer from 0 to 4; A represents a group selected from —CH 2 —, —CH═CR 9 —, —CR 9 ═CH—, —CR 9 R 10 —, —CO—, —O—, —S—, —S(O)—, —S(O) 2 — and NR 9 , wherein R 9 and R 10 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; m is an integer from 0 to 8, provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azonia bicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; R 4 represents a group of structure: (Formulae II) wherein R 11 represents a hydrogen or halogen atom, a hydroxy group, an alkoxy group, a nitro group, a cyano group, —CO 2 R 12 or —NR 12 R 13 , wherein R 12 and R 13 are identical or different and are selected from hydrogen and straight or branched lower alkyl groups, or a straight or branched, substituted or unsubstituted lower alkyl group; R 5 represents an alkyl group of 1 to 7 carbon atoms, an alkenyl group containing 2 to 7 carbon atoms, or a group of formula (III) wherein q=1 or 2 and R 11 iss a defined above; R 6 represents a hydrogen atom, a hydroxy group, a methyl group or a —CH 2 OH group; and X − represents a pharmaceutically acceptable anion of a mono or polyvalent acid. 1

  式(I)的化合物，其中B是苯环、含有一个或多个杂原子的5至10元杂芳香族基团，或萘基、5,6,7,8-四氢萘基、苯并[1,3]二氧杂环戊基或联苯基团；R1、R2和R3各自独立地表示氢或卤素原子，或羟基、苯基、—OR7、—SR7、—NR7R8、—NHCOR7、—CONR7R8、—CN、—NO2、—COOR7或CF3基团，或直链或支链、取代或未取代的低级烷基基团，其中R7和R8各自独立地表示氢原子、直链或支链的低级烷基基团，或一起形成脂环族环；或者R1和R2一起形成芳香族或脂环族环或杂环基团。n是0至4的整数；A表示选自—CH2—、—CH═CR9—、—CR9═CH—、—CR9R10—、—CO—、—O—、—S—、—S(O)—、—S(O)2—和NR9的基团，其中R9和R10各自独立地表示氢原子、直链或支链的低级烷基基团，或一起形成脂环族环；m是0至8的整数，条件是当m=0时，A不是—CH2—；p是1至2的整数，并且氮杂双环环上的取代可以在2、3或4位，包括所有可能的不对称碳构型；R4表示具有结构：(式II)的基团，其中R11表示氢或卤素原子、羟基、烷氧基、硝基、氰基、—CO2R12或—NR12R13，其中R12和R13相同或不同，并选自氢和直链或支链的低级烷基基团，或直链或支链、取代或未取代的低级烷基基团；R5表示1至7个碳原子的烷基基团、含有2至7个碳原子的烯基基团，或具有式(III)的基团，其中q=1或2，且R11如上定义；R6表示氢原子、羟基、甲基或—CH2OH基团；X-表示药物上可接受的单或多元酸的阴离子。
• [EN] NEW QUATERNIZED QUINUCLIDINE ESTERS<br/>[FR] NOUVEAUX ESTERS DE QUINUCLIDINE QUATERNISES
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2005090342A1

  公开（公告）日：2005-09-29

  Compounds of formula (1) wherein the different substituents and/or radicals have the values defined in the claims. The invention also relates to a process for the preparation of said compounds, to pharmaceutical compositions comprising them, as well as to combinations of said compounds with other compounds which are active in the treatment of respiratory, urological or gastrointestinal disorders or diseases. Finally the invention also relates to the use of the compounds of formula (I) for the treatment of respiratory, urological or gastrointestinal disorders or diseases.

  公式（1）中的化合物，其中不同的取代基和/或基团具有权利要求中定义的值。本发明还涉及一种制备所述化合物的方法，包括含有它们的药物组合物，以及含有其他对治疗呼吸道、泌尿系统或消化系统疾病有活性的化合物与所述化合物的组合物。最后，本发明还涉及利用公式（I）的化合物治疗呼吸道、泌尿系统或消化系统疾病的用途。
• Quaternized Quinuclidine Esters
  申请人：Fernandez Forner Maria Dolors

  公开号：US20080214600A1

  公开（公告）日：2008-09-04

  Compounds of formula (I) wherein the different substituents and/or radicals have the values defined in the claims. The invention also relates to a process for the preparation of said compounds, to pharmaceutical compositions comprising them, as well as to combinations of said compounds with other compounds which are active in the treatment of respiratory, urological or gastrointestinal disorders or diseases. Finally the invention also relates to the use of the compounds of formula (I) for the treatment of respiratory, urological or gastrointestinal disorders or diseases.

  公式(I)的化合物，其中不同的取代基和/或基团具有在权利要求中定义的值。本发明还涉及制备所述化合物的方法，包括它们的制药组合物，以及与其他用于治疗呼吸系统，泌尿系统或胃肠道紊乱或疾病的化合物的组合。最后，本发明还涉及使用公式(I)的化合物治疗呼吸系统，泌尿系统或胃肠道紊乱或疾病的用途。
• NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：PRAT QUINONES Maria

  公开号：US20100234332A1

  公开（公告）日：2010-09-16

  A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl. 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R 1 , R 2 and R 3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group, —OR 7 , —SR 7 , —NR 7 R 8 , —NHCOR 7 , —CONR 7 R 8 , —CN, —NO 2 , —COOR 7 or CF 3 group, or a strait or branched, substituted or unsubstituted lower alkyl group, wherein R 7 and R 8 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; or R 1 and R 2 together form an aromatic or alicyclic ring or a heterocyclic group. n is an integer from 0 to 4; A represents a group selected from —CH 2 —, —CH═CR 9 —, —CR 9 ═CH—, —CR 9 R 10 —, —CO—, —O—, —S—, —S(O)—, —S(O) 2 — and NR 9 , wherein R 9 and R 10 each independently represent a hydrogen atom, a straight or branched lower alkyl group, or together form an alicyclic ring; m is an integer from 0 to 8, provided that when m=0, A is not —CH 2 —; p is an integer from 1 to 2 and the substitution in the azonia bicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; R 4 represents a group of structure: (Formulae II) wherein R 11 represents a hydrogen or halogen atom, a hydroxy group, an alkoxy group, a nitro group, a cyano group, —CO 2 R 12 or —NR 12 R 13 , wherein R 12 and R 13 are identical or different and are selected from hydrogen and straight or branched lower alkyl groups, or a straight or branched, substituted or unsubstituted lower alkyl group; R 5 represents an alkyl group of 1 to 7 carbon atoms, an alkenyl group containing 2 to 7 carbon atoms, or a group of formula (III) wherein q=1 or 2 and R 11 is a defined above; R 6 represents a hydrogen atom, a hydroxy group, a methyl group or a —CH 2 OH group; and X − represents a pharmaceutically acceptable anion of a mono or polyvalent acid.

  化合物的公式（I），其中B是苯环，含有一个或多个杂原子的5到10个成员的杂芳族基团，或萘基，5,6,7,8-四氢萘基，苯并[1,3]二噁英基或联苯基；R1，R2和R3各自代表氢或卤素原子，或羟基，苯基，-OR7，-SR7，-NR7R8，-NHCOR7，-CONR7R8，-CN，-NO2，-COOR7或CF3基团，或直链或支链，取代或未取代的较低烷基基团，其中R7和R8各自代表氢原子，直链或支链较低烷基基团，或一起形成脂环；或R1和R2一起形成芳香族或脂环或杂环基团。n为0到4的整数；A表示从-CH2，-CH═CR9，-CR9═CH-，-CR9R10，-CO-，-O-，-S-，-S（O）-，-S（O）2-和NR9中选择的基团，其中R9和R10各自代表氢原子，直链或支链较低烷基基团，或一起形成脂环；m为0到8的整数，前提是当m=0时，A不是-CH2-；p为1到2的整数，并且氮杂双环环中的取代基可以在2、3或4位，包括不对称碳的所有可能构型；R4表示结构的基团：（公式II），其中R11表示氢或卤素原子，羟基，烷氧基，硝基，氰基，-CO2R12或-NR12R13，其中R12和R13相同或不同，并选择自氢和直链或支链较低烷基基团，或直链或支链，取代或未取代的较低烷基基团；R5表示1到7个碳原子的烷基基团，含有2到7个碳原子的烯基基团，或公式（III）中的基团，其中q=1或2且R11如上所述；R6表示氢原子，羟基，甲基或-CH2OH基团；X-表示单价或多价酸的药用可接受的阴离子。
• NEW QUATERNIZED QUINUCLIDINE ESTERS
  申请人：Laboratorios Almirall, S.A.

  公开号：EP1725552B1

  公开（公告）日：2008-06-25